<DOC>
	<DOCNO>NCT01470027</DOCNO>
	<brief_summary>The overall objective developmental/exploratory study use noninvasive proton magnetic resonance spectroscopy ( 1H MRS ) determine ( ) whether level antioxidant glutathione ( GSH ) decrease vivo , find postmortem brain , brain 30 patient Parkinson 's disease ( PD ) compare matched control ; ( b ) whether GSH level PD brain increase significantly follow 30 day daily supplementation 1800mg 3600mg N-acetylcysteine ( NAC ) compare placebo baseline , ( c ) whether increase brain GSH would dose-dependent associated change participant ' oxidative stress profile . In addition , clinical assessment battery , include quantitative test motor function , perform investigate potential association NAC intervention , brain GSH level , oxidative stress marker , clinical presentation . If successful , study represent first objective documentation whether GSH deficit live PD brain dietary NAC supplementation mitigate , thereby provide compel justification investigate neuroprotective strategy large control clinical trial .</brief_summary>
	<brief_title>N-Acetylcysteine Neuroprotection Parkinson 's Disease</brief_title>
	<detailed_description>Multiple line preclinical , animal model , genetic postmortem evidence implicate oxidative stress chain pathogenic event lead progressive degeneration nigrostriatal dopaminergic neuron find Parkinson 's disease ( PD ) - hallmark disorder . These include evidence membrane lipid peroxidation see increase level 8-iso-prostaglandin-F2a-isoprostanes ( F2-isoprostanes ) ( Seet et al 2010 ) , protein peroxidation form nitration nitrosylation a-synuclein parkin ( Giasson et al 2000 ; Chung et al 2004 ; Yao et al 2004 ) , oxidative DNA damage measure increase 8-hydroxy-2-deoxyguanosine ( 8OH'2dg ) ( Alam et al 1997 ; Seet et al 2010 ; Nakabeppu et al 2007 ) . Importantly , replicate study postmortem PD brain independent laboratory ( Sofic et al 1992 ; Jenner 1992 et al ; Riederer et al 1989 ; Sian et al 1994 ) consistently find loss 40 % nigral glutathione ( GSH ) , abundant antioxidant living tissue , suggest oxidative stress PD may result decreased intracellular antioxidant capacity ( Bains Shaw 1997 ) . Therefore , currently great interest neuroprotective treatment strategy aim maintaining , restore and/or elevate intracellular GSH level ( Zeevalk 2008 ) . However , GSH readily cross blood-brain barrier membrane cell , include neuron , direct dietary supplementation antioxidant prove viable increase intracellular concentration ( Zeevalk 2008 ) . On hand , since bioavailability cysteine , cross blood-brain barrier cell membrane , rate-limiting GSH synthesis pathway , amino acid non-toxic derivative , N-acetylcysteine ( NAC ) , investigate potential precursor supply dietary mean spur situ synthesis intracellular elevation brain GSH ( Zeevalk 2008 ) . In support potential validity strategy , two recent study schizophrenia ( Berk et al 2008b ; Bulut et al 2009 ) one bipolar disorder ( Berk et al 2008c ) - disorder oxidative stress postulate play pathogenic role -- report symptom amelioration follow treatment NAC . However , best knowledge , study date measure vivo human brain GSH PD confirm 40 % deficit antioxidant find postmortem brain , ascertain NAC supplementation lead elevation brain GSH situ . The overall objective R21 proposal , therefore , address void gap knowledge pursue follow aim : Specific Aim 1 : To directly measure , use proton magnetic resonance spectroscopy ( 1H MRS ) , vivo brain GSH 30 unmedicated patient idiopathic PD 30 sex- age-matched healthy control prior follow 4 week supplementation either placebo , 2000mg/day 4000 mg/day NAC . Hypothesis 1 : ( ) Baseline brain GSH level significantly low patient PD match healthy control subject . ( b ) Brain level GSH increase significantly compare baseline treat group follow 4 week NAC supplementation . However , elevation antioxidant dose-dependent large subject large deficit baseline . Specific Aim 2 : To measure number establish marker oxidative stress ( Dalle-Donne et al 2006 ) temporally concordant CSF sample obtain participant , baseline follow 4 week NAC supplementation . Hypothesis 2 : ( ) Four week NAC supplementation improve oxidative stress profile subject , large improvement occur subject large baseline GSH deficit . ( b ) Because GSH cross blood-brain barrier , level CSF well correlate brain level measure 1H MRS would blood level , provide accurate assessment antioxidant capacity oxidative stress CNS . Significance : Achievement aim provide first objective vivo documentation report postmortem brain GSH deficit oxidative stress PD , whether NAC supplementation increase brain level antioxidant situ , thereby provide compel justification large placebo-controlled , randomized trial NAC neuroprotective therapy . This proposal qualify `` high-risk , high-reward '' since tackle significant scientific therapeutic roadblock , overcome , could open new avenue PD therapy development .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>Diagnosis idiopathic PD accord United Kingdom Parkinson 's Disease Society Brain Bank criterion ( UKPDSBB ) criterion ( PD group Age 50 75 year Able give inform consent study participation Not medication PD ( anticholinergic agent allow ) Unable give inform consent Unable undergo brain MRI PD duration ≥15 year Receiving dopamine receptor block agent , include typical neuroleptic , prochlorperazine , metoclopramide Diagnosis major depression axis I psychopathology Modified MiniMental Status Exam ( MMSE ) ≤ 24/30 Diagnosis chronic persistent illness could affect oxidative stress status , diabetes congestive heart failure Significant concomitant medical disease limit life expectancy le 12 month study inclusion Diagnosis primary mitochondrial disorder , epilepsy , stroke , multiple sclerosis neurodegenerative diseases Alzheimer 's disease ALS</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>magnetic resonance spectroscopy</keyword>
	<keyword>N-acetylcysteine</keyword>
	<keyword>antioxidant</keyword>
	<keyword>glutathione</keyword>
</DOC>